BD (Becton, Dickinson and Company), a global leading medical technology company, announced on Aug 8 that it had commenced mass production of its high-end FACSLyric flow cytometer in China. This marks a milestone in the implementation of the company’s localization strategy.
The localized production of the FACSLyric flow cytometer is undertaken by BD Rapid Diagnostic Products (Suzhou) Co Ltd, BD’s branch in SIP. It is based on BD’s deep insight into China’s needs for products of such kind and development potential.
Flow cytometry, widely used in life sciences, clinical diagnostics and drug development, is gaining strong momentum in the country due to rising biomedical investment and expanding clinical needs. The localized BD FACSLyric production line combines advanced performance with a service infrastructure designed specifically for the Chinese market, including on-site installation, application training, and customized support.
It is learned that by aligning global expertise with China’s healthcare demands, BD aims to deliver advanced solutions tailored for local needs while contributing to the global development of flow cytometry. This follows earlier localization of consumables and extends to full value chain integration from manufacturing to technical support.
August 8, 2025
